Want to see DNLI full AI Analyst Report?
DNLI Stock Chart & Stats
$24.93
-$0.31(-1.32%)
At close: 4:00 PM EDT
$24.93
-$0.31(-1.32%)
Day’s Range― - ―
52-Week Range$13.75 - $27.30
Previous CloseN/A
Volume1.16M
Average Volume (3M)1.84M
Market Cap
$2.88B
Enterprise Value$4.14B
Total Cash (Recent Filing)$710.47M
Total Debt (Recent Filing)$27.50M
Price to Earnings (P/E)―
Beta1.92
Next Earnings
Nov 11, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.84
Shares Outstanding159,847,400
10 Day Avg. Volume2,015,834
30 Day Avg. Volume1,839,210
Financial Highlights & Ratios
PEG Ratio-0.36
Price to Book (P/B)2.86
Price to Sales (P/S)0.00
P/FCF Ratio-6.86
Enterprise Value/Market Cap1.44
Enterprise Value/Revenue1.15K
Enterprise Value/Gross Profit-1.88K
Enterprise Value/Ebitda-8.32
Forecast
1Y Price Target
$36.11Price Target Upside44.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-2.29
Revenue Forecast (FY)$38.83M
Bulls Say, Bears Say
Bulls Say
Strong Balance SheetVery low leverage and a sizable asset base give Denali meaningful financial flexibility while it develops its pipeline and supports commercialization. The balance sheet can fund research, launch execution, and clinical milestones with less dependence on near-term external financing.
AVLAYAH Commercialization And AccessAVLAYAH has moved Denali from a purely clinical business into commercialization, while broad early payer coverage supports patient access and adoption. Revenue guidance and established reimbursement pathways create a foundation for a potentially durable commercial franchise.
Validated ETV Platform And PipelineRegulatory approval validates Denali's transport vehicle approach for delivering a CNS-penetrant biologic, reducing platform proof-of-concept risk. Reusing this technology across neurologic and lysosomal disease programs could create multiple shots on goal beyond AVLAYAH.
Bears Say
Severe Cash Burn And LossesThe company remains heavily dependent on its cash resources because operating activities consume substantial capital and profitability is far away. Persistent burn can constrain investment choices over time and increases the importance of successful commercialization and pipeline execution.
Weak And Inconsistent Revenue BaseRevenue remains too small and inconsistent to offset Denali's substantial research and commercial expenses. This leaves earnings power unproven and makes the business financially sensitive to the pace of AVLAYAH uptake, reimbursement, and future product launches.
Launch And Pipeline Execution UncertaintyVariable patient initiation and infusion-center capacity may make commercial growth uneven, while delayed or long-dated clinical readouts extend the period before pipeline value can be assessed. Together, these factors create execution risk across both current revenue and future catalysts.
Denali Therapeutics News
DNLI FAQ
What was Denali Therapeutics’s price range in the past 12 months?
Denali Therapeutics lowest stock price was $13.75 and its highest was $27.30 in the past 12 months.
What is Denali Therapeutics’s market cap?
Denali Therapeutics’s market cap is $2.88B.
When is Denali Therapeutics’s upcoming earnings report date?
Denali Therapeutics’s upcoming earnings report date is Nov 11, 2026 which is in 22 days.
How were Denali Therapeutics’s earnings last quarter?
Denali Therapeutics released its earnings results on Aug 06, 2026. The company reported -$0.68 earnings per share for the quarter, missing the consensus estimate of -$0.513 by -$0.167.
Is Denali Therapeutics overvalued?
According to Wall Street analysts Denali Therapeutics’s price is currently Undervalued.
Does Denali Therapeutics pay dividends?
Denali Therapeutics does not currently pay dividends.
What is Denali Therapeutics’s EPS estimate?
Denali Therapeutics’s EPS estimate is -0.32.
How many shares outstanding does Denali Therapeutics have?
Denali Therapeutics has 159,847,400 shares outstanding.
What happened to Denali Therapeutics’s price movement after its last earnings report?
Denali Therapeutics reported an EPS of -$0.68 in its last earnings report, missing expectations of -$0.513. Following the earnings report the stock price went up 0.404%.
Which hedge fund is a major shareholder of Denali Therapeutics?
Currently, no hedge funds are holding shares in DNLI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Denali Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.11 (44.85% Upside)
$36.11 (44.85% Upside)
Blogger Sentiment
Neutral
DNLI Sentiment 50%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 4.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $108.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
8.28%
12-Months-Change
Fundamentals
Return on Equity
-55.27%
Trailing 12-Months
Asset Growth
-0.71%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Denali Therapeutics
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease. Another candidate, DNL310, is progressing through Phase 1/2 clinical studies for Hunter syndrome. For amyotrophic lateral sclerosis (ALS), DNL343 is in Phase 1 trials, while AR443820/DNL788 has successfully concluded its Phase 1 clinical trial for ALS, multiple sclerosis (MS), and Alzheimer's disease. Furthermore, SAR443122/DNL758 is undergoing Phase 2 clinical trials for cutaneous lupus erythematosus. Denali Therapeutics is engaged in extensive collaborative efforts with a range of partners, including Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. It also maintains a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG to co-develop antisense therapies specifically for neurodegenerative diseases.
DNLI Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call communicated a strong, constructive start to commercialization with meaningful early revenue ($3.6M), rapid payer progress (>50% commercial lives) and platform validation via AVLAYAH, supported by a robust pro forma cash position (> $1.1B) and multiple clinical programs advancing toward 2027 readouts. Near-term challenges include variability in revenue and patient initiation timing due to weight-based dosing and infusion logistics, limited disclosed patient-level metrics, some program timing shifts (DNL593), and competitive/coverage risks. On balance, the positive commercial and platform milestones materially outweigh the near-term operational and timing uncertainties.View all DNLI earnings summariesDNLI Stock 12 Month Forecast
Average Price Target
$36.11
▲(44.85% Upside)
Technical Analysis
Ownership Overview
5.13% Insiders
23.95% Mutual Funds
0.04% Other Institutional Investors
51.63% Public Companies and
Individual Investors